Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins.
about
New world bats harbor diverse influenza A virusesOptimal Use of Vaccines for Control of Influenza A Virus in SwineA contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virusInfluenza virus neuraminidase (NA): a target for antivirals and vaccines.Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.Emerging influenza viruses and the prospect of a universal influenza virus vaccine.Influenza Neuraminidase Subtype N1: Immunobiological Properties and Functional Assays for Specific Antibody Response.Long-Lasting Cross-Protection Against Influenza A by Neuraminidase and M2e-based immunization strategiesRecombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferretsInactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner.Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin.Targets for the induction of protective immunity against influenza a viruses.A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virusVirus-like particles as universal influenza vaccinesNeuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccineUsing sequence data to infer the antigenicity of influenza virus.Differential ability of B cells specific for external vs. internal influenza virus proteins to respond to help from influenza virus-specific T-cell clones in vivo.In the shadow of hemagglutinin: a growing interest in influenza viral neuraminidase and its role as a vaccine antigen.Enhancement of SIV-specific cell mediated immune responses by co-administration of soluble PD-1 and Tim-3 as molecular adjuvants in mice.Immunization with purified N1 and N2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition.Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice.Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines.Impaired peripheral blood T-follicular helper cell function in HIV-infected nonresponders to the 2009 H1N1/09 vaccinePeptide component vaccine engineering: targeting the AIDS virus.Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection.Class I H-2d-restricted cytotoxic T lymphocytes recognize the neuraminidase glycoprotein of influenza virus subtype N1.Cellular and humoral immune responses to rubella virus structural proteins E1, E2, and C.A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2.Antibody Responses to Trivalent Inactivated Influenza Vaccine in Health Care Personnel Previously Vaccinated and Vaccinated for The First Time.Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins.Human influenza vaccines and assessment of immunogenicity.Correlates of vaccine protection from influenza and its complications.Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults.Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition.Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection.Kinetics, longevity and cross-reactivity of anti-neuraminidase antibody after natural infection with influenza A viruses.Prospects for universal influenza virus vaccine.The S128N mutation combined with an additional potential N-linked glycosylation site at residue 133 in hemagglutinin affects the antigenicity of the human H7N9 virus.Influenza Infection in Humans Induces Broadly Cross-Reactive and Protective Neuraminidase-Reactive Antibodies.NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?
P2860
Q21090482-38C7106C-B9F8-46CF-818C-745A029401B9Q26783503-36FE6960-8BF4-47B7-BF78-CD6953E692DAQ27316330-A182306E-FA9F-4641-9E8F-CADE9F9D8231Q30249879-906699B9-C23A-478A-84C8-2A32C110ABD0Q30359842-61241319-B7D5-47E9-B9A7-DF5C32E59E02Q30372274-F1B5835B-B1BE-4267-9C9C-0DDC6BFD180EQ30386612-E1E19DEF-9068-40C1-80B1-E6E62F3F14BCQ30386823-55EC9B17-7A9B-4BC2-90CA-697139296823Q30392305-AD2B346C-08E9-4EEF-B94E-8B59F8DEBE4CQ30395315-5F644486-6C80-4ED6-9D8A-31981C2B432EQ30400179-7B37DE96-9002-48CF-A95C-A701C9D4B3A1Q30408100-466089D5-1AE1-4568-A0DD-732893FF0262Q30420210-AB8FF930-59C2-46E1-A872-2B0B94DF8212Q30421558-1078DC60-FE30-44A7-8BD9-36FB91478A0BQ30425439-4B0C41AD-8285-4734-B9C3-7E2B9C8F9324Q30652766-B18B1CA8-3C55-40CE-A84E-30882DB4BB25Q33582453-DF4C4DD5-6B9B-4803-8B32-52599F7FE7B3Q33820732-B66D8AF8-5ED6-48EB-BE06-327682159B58Q34033862-7C91C29D-DA32-4ACA-98B6-A95167CE765DQ35109380-C1471C3E-5703-4CC7-BEED-FE3E96F3F015Q35677624-427F4906-8A0C-413D-B926-C58124706078Q36075789-AF824C8B-4549-4839-B219-7ECFD087D29AQ36141874-DB3D5A4D-2861-4B11-8E35-C94B671AAEFFQ36708999-0AA181CF-ABAA-4569-A0C8-C99FC0790EF4Q36781677-CBC77728-1B10-4D77-8FB4-22CAED300653Q36801887-05F4D512-4A42-4BF7-9C3A-3D66A39C4E8FQ37126576-7306015C-D91C-462A-8CFC-D93E5C05D71FQ37547653-B7B15FE0-CDBD-4383-B024-356FCD4D39E1Q37591325-408A61F6-6B9C-48D2-91D1-3A1C947CAFB6Q37678602-16B019D6-08D9-4CE5-A7F4-5205D96C2E34Q37812125-34E585A3-BA72-453D-A9D0-E6B5F8E14687Q37976539-D984FA53-CB4D-453A-8921-15BDFA57CF3CQ39810755-5F0C5529-244A-4F5F-B77B-385981A5F853Q40047277-59CFA4E9-D95D-4253-85DA-C0AC06CE7750Q41378999-DAA55BDC-BA47-477C-9CAF-5C8C88E22160Q41918783-DE796AAA-3058-48C7-B589-23FA23A2D7B6Q41988078-DFEB0EA6-4019-4531-9A93-7844C99892F2Q42381827-6CD8F97D-FC7B-48E5-B269-5DA259DBECA1Q52602393-365C83A0-FA93-43DE-AA3D-BB03E7891B20Q52609074-CE65AC05-321B-487B-8FA1-399920D56838
P2860
Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins.
description
1987 nî lūn-bûn
@nan
1987 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
name
Antigen-presenting B cells and ...... A virus surface glycoproteins.
@ast
Antigen-presenting B cells and ...... A virus surface glycoproteins.
@en
Antigen-presenting B cells and ...... A virus surface glycoproteins.
@nl
type
label
Antigen-presenting B cells and ...... A virus surface glycoproteins.
@ast
Antigen-presenting B cells and ...... A virus surface glycoproteins.
@en
Antigen-presenting B cells and ...... A virus surface glycoproteins.
@nl
prefLabel
Antigen-presenting B cells and ...... A virus surface glycoproteins.
@ast
Antigen-presenting B cells and ...... A virus surface glycoproteins.
@en
Antigen-presenting B cells and ...... A virus surface glycoproteins.
@nl
P2093
P2860
P356
P1476
Antigen-presenting B cells and ...... A virus surface glycoproteins.
@en
P2093
B E Johansson
E D Kilbourne
P2860
P304
P356
10.1073/PNAS.84.19.6869
P407
P577
1987-10-01T00:00:00Z